MDL-2592 Xarelto LitigationThe Plaintiffs’ Leadership, which includes Herman, Herman & Katz, LLC partner, Leonard A. Davis (Co-Plaintiffs’ Liaison Counsel), and Defendants, Bayer Healthcare and Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, entered into an Agreement/Memorandum of Understanding (“MOU”) on March 25, 2019 to create a program to end the Xarelto® litigation across the country and to resolve claims involving injuries alleged to have resulted from the use of XARELTO®.  Full details regarding the Settlement Program will be available in the next few weeks, which will include information concerning registration of claims and eligibility requirements.  The aggregate settlement amount is $775,000,000.00.  The Settlement Program will resolve all claims between Plaintiffs and Defendants, and a Claims Administrator and Special Master will be appointed to manage the claims process.  Questions regarding the settlement or Xarelto claims should be directed to Regina Valenti at Herman, Herman & Katz, LLC.